MedPath

Comparison of Absorption of Budesonide and Formoterol From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler

Phase 1
Completed
Conditions
Asthma
Interventions
Drug: Symbicort Turbuhaler forte
Drug: Charcoal and Symbicort Turbuhaler
Drug: Charcoal and Budesonide/formoterol Easyhaler 320/9 microg
Drug: Budesonide/formoterol Easyhaler 320/9 microg
Registration Number
NCT01593826
Lead Sponsor
Orion Corporation, Orion Pharma
Brief Summary

The purpose of this study is to compare the test product Budesonide/formoterol Easyhaler with the marketed product Symbicort Turbuhaler in terms of the drug absorbed into the bloodstream.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
72
Inclusion Criteria
  1. Healthy males and females aged 18-60 years.
  2. Normal weight, at least 50 kg.
Read More
Exclusion Criteria
  1. Evidence of a clinically significant cardiovascular, renal, hepatic, haematological, GI, pulmonary, metabolic-endocrine, neurological or psychiatric disease.
  2. Any clinically significant abnormal laboratory value or physical finding that may interfere with the interpretation of study results or constitute a health risk for the subject if he/she takes part in the study.
  3. Any condition requiring regular concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during the study.
  4. Known hypersensitivity to the active substance(s) or the excipient of the drug.
  5. Pregnant or lactating females.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Symbicort TurbuhalerSymbicort Turbuhaler forte-
Charcoal and Symbicort TurbuhalerCharcoal and Symbicort Turbuhaler-
Charcoal and Budesonide/formoterol EasyhalerCharcoal and Budesonide/formoterol Easyhaler 320/9 microg-
Budesonide/formoterol EasyhalerBudesonide/formoterol Easyhaler 320/9 microg-
Primary Outcome Measures
NameTimeMethod
Pharmacokinetic parameter Cmax of plasma budesonide concentrationwithin 12 h
Pharmacokinetic parameter Cmax of plasma formoterol concentrationwithin 24 h
Pharmacokinetic parameter AUCt of plasma budesonide concentrationWithin 12 h
Pharmacokinetic parameter AUCt of plasma formoterol concentrationWithin 24 h
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Orion Pharma Clinical Pharmacology Unit

🇫🇮

Espoo, Finland

© Copyright 2025. All Rights Reserved by MedPath